FPN’s Advocacy Program: Spotlight on a Peer Reviewer
Ron Lissak, one of FPN’s board members, has served as a patient expert of our government-funded Peer Reviewed Medical Research Program (PRMRP), that is focused on peripheral neuropathy as one of the topic areas.
EBike Tour Video: From Carson City in Nevada to the Finish Line in San Francisco
Gregory Maassen, FPN fundraiser and eBike enthusiast, gives an update on his one-person e-bike convoy traveling across America. He arrived at the finish line in San Francisco, California, after cycling 4,685.8 miles in four months.
Demystifying Diabetic Peripheral Neuropathy
On September 7, Dr. Rodica Pop-Busui from Michigan Medicine joined the Foundation for a special presentation on diabetic neuropathy, from causes to treatments and everything in between. If you were unable to join us for this program, please click here to access the recording.
This article from MedPageToday also highlights some additional approaches for treating one’s diabetic PN, focusing on a combination of treatments, which the Foundation has shown to work best for all causes of neuropathy.
Amyloidosis: An Overview
Amyloidosis is a rare disorder that happens when proteins in your body change or mutate, turning into twisted clumps of misshapen proteins that gather on your organs and tissues. Some amyloidosis types affect specific organs, such as your heart, kidneys, liver and lungs. Other types spread throughout your body and impact one’s nerves. Treatments include organ transplantation, chemotherapy or targeted therapies.
CIPN: Eight FAQs and Answers
In this article, Memorial Sloan Kettering Cancer Center physiatrist Jesuel Padro-Guzman answers eight common questions about peripheral neuropathy induced by chemotherapy – also known as CIPN. As a rehabilitation medicine doctor, Dr. Padro-Guzman cares for many patients with CIPN.
The Foundation for Peripheral Neuropathy provides education and support today as we walk toward a cure for tomorrow.
Support us in advancing a cure!
FPN is a non-profit organization that is solely funded by our readers.